Generalizability Limitations of Single Case Reports

547 concepts584 papers31 proposals

In clinical research, the case report serves as the "first responder." It identifies rare diseases, documents unexpected drug reactions, and proposes novel surgical techniques long before they reach the rigor of a randomized controlled trial. However, a recurring theme across hundreds of clinical observations—from rare metabolic disorders to advanced oncology—is the inherent epistemic boundary of the "N-of-1" study: the inability to generalize findings from a single individual to a broader population.

The Proof of Existence vs. The Proof of Pattern

The primary value of a case report is to demonstrate that a specific clinical event is possible. For instance, Teru Hideshima et al. demonstrated in A RESECTED CASE OF ADVANCED ESOPHAGEAL CARCINOMA SHOWING A PROMINENT RESPONSE TO NEOADJUVANT CHEMOTHERAPY WITH 5-FU AND LEUCOVORIN that a massive, inoperable tumor could be reduced by 94% using low-dose chemotherapy. While this provides a vital signal for future research, the authors explicitly note that a sample size of one makes it impossible to assess whether this response is a reproducible oncological pattern or a biological outlier.

This limitation is particularly acute when identifying pathogens. H. Watanabe et al. identified Porphyromonas gingivalis as a driver of severe bone loss in a patient with hypophosphatasia in A Case of Severe Periodontal Disease in Adolesence Associated with Hypophosphatasia.. Yet, the authors caution that these immunological findings might be unique to that specific 15-year-old patient rather than a universal characteristic of the metabolic disorder itself.

The Noise of Biological Variance

Why does generalizability fail at the single-case level? The answer lies in the "noise" of individual patient characteristics—genetics, performance status, and comorbidities—which can mask the true cause of a clinical outcome.

When Jiayu Zhou et al. performed a successful complex surgery on a 92-year-old in Laparoscopic pancreaticoduodenectomy in A-92-older Chinese patient for cancer of head of the pancreas, they noted that the success might be due to that specific patient’s high performance status rather than the surgical approach itself. Similarly, Kazuhiro Yasuda et al. pointed out in Gastrectomy for a patient with early gastric cancer and human immunodeficiency virus (HIV) infection that their success in an HIV-positive patient cannot be extrapolated to those with higher viral loads or more compromised immune systems.

In these instances, the individual is not a representative proxy for the group. As Georges El Hasbani argues in Vertebral artery dolichoectasia leading to hemifacial spasm, conclusions drawn from one experience simply lack the statistical power to account for the diversity of human biology.

From Anecdote to Standard of Care

The transition from a case report to a medical standard requires the validation of frequency and safety across diverse cohorts. A single success, such as the use of low-dose IL-2 to treat immunotherapy-induced skin disease reported by Yingyue Zhang et al. in Case report: Low-dose interleukin-2: a treatment of bullous pemphigoid with predominantly perifollicular blistering caused by PD-1/PD-L1 inhibitor, provides a promising lead. However, the authors emphasize that without larger controlled trials, the therapeutic response cannot be confirmed as reproducible.

The same logic applies to rare complications. In Continuous cement leakage along the posterior longitudinal ligament of the intraspinal epidural during a percutaneous vesselplasty: A case report and literature review, Sijia Guo et al. describe a specific type of surgical leakage. Because the study relies on one patient, the frequency of this event remains unknown, preventing the establishment of a statistically significant risk profile.

Ultimately, while case reports like those by Jianzheng Wang et al. on PD-1 inhibitors in A PD-1 Inhibitor Induces Complete Response of Advanced Bladder Urothelial Carcinoma: A Case Report offer vital glimpses into potential cures, they function as the beginning of the scientific conversation, not the final word. The "limitation" of the single case is not a failure of the format, but a necessary boundary of its statistical design.

History & citationVersion 2 · 2026-10-04

Current · Permanent link

  1. Version 2 (latest) · 2026-10-04 · 543 papers
  2. Version 1 · 2026-10-04 · 785 papers
Cite this direction

Latest version (a living page):

@misc{lacuna_single_case_study_limitation_7241ca47,
  title = {single case study limitation},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/single-case-study-limitation/rdr_7241ca47e1f9451e8cb4468d275e88cf},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 2, frozen text):

@misc{lacuna_single_case_study_limitation_7241ca47_v2,
  title = {single case study limitation},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/single-case-study-limitation/rdr_7241ca47e1f9451e8cb4468d275e88cf/v/2},
  note = {Version 2, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake